ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Stock analysts at HC Wainwright increased their Q1 2025 EPS estimates for ArriVent BioPharma in a research note issued to investors on Wednesday, January 22nd. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.78) per share for the quarter, up from their prior forecast of ($0.81). HC Wainwright has a "Buy" rating and a $39.00 price objective on the stock. The consensus estimate for ArriVent BioPharma's current full-year earnings is ($2.74) per share. HC Wainwright also issued estimates for ArriVent BioPharma's Q2 2025 earnings at ($0.84) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.91) EPS and FY2025 earnings at ($3.41) EPS.
ArriVent BioPharma Price Performance
AVBP stock traded up $0.05 during midday trading on Friday, hitting $27.30. 96,493 shares of the company's stock were exchanged, compared to its average volume of 133,826. ArriVent BioPharma has a 1-year low of $14.35 and a 1-year high of $36.37. The business has a 50-day simple moving average of $26.99 and a two-hundred day simple moving average of $26.03.
Institutional Trading of ArriVent BioPharma
Hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. purchased a new position in ArriVent BioPharma in the fourth quarter worth approximately $190,000. Rhumbline Advisers lifted its position in shares of ArriVent BioPharma by 30.1% during the 2nd quarter. Rhumbline Advisers now owns 12,707 shares of the company's stock worth $236,000 after purchasing an additional 2,942 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of ArriVent BioPharma during the 3rd quarter worth $240,000. SG Americas Securities LLC acquired a new position in shares of ArriVent BioPharma during the third quarter worth $280,000. Finally, JPMorgan Chase & Co. increased its holdings in ArriVent BioPharma by 183.2% in the third quarter. JPMorgan Chase & Co. now owns 12,445 shares of the company's stock valued at $292,000 after buying an additional 8,050 shares during the last quarter. Institutional investors and hedge funds own 9.48% of the company's stock.
ArriVent BioPharma Company Profile
(
Get Free Report)
ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.
Featured Stories
Before you consider ArriVent BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ArriVent BioPharma wasn't on the list.
While ArriVent BioPharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
